Setmelanotide
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Rhythm · Phase 3 · Completed · Enrollment 296
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| POMC or PCSK1 variant | n/r | n/r | n/r | n/r |
| LEPR variant | n/r | n/r | n/r | n/r |
| NCOA1 (SRC1) variant | n/r | n/r | n/r | n/r |
| SH2B1 variant | n/r | n/r | n/r | n/r |
Not shown
- POMC or PCSK1 variant: endpoint not reported
- LEPR variant: endpoint not reported
- NCOA1 (SRC1) variant: endpoint not reported
- SH2B1 variant: endpoint not reported